Skip to main content
Erschienen in: Reactions Weekly 1/2017

01.06.2017 | Case report

Ipilimumab/nivolumab/pembrolizumab

Cutaneous erythematous papular eruptions, autoimmune hepatitis and pancreatitis: 11 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literatur
Zurück zum Zitat Perret RE, et al. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma. International Journal of Dermatology 56: 527-533, No. 5, May 2017. Available from: URL: http://doi.org/10.1111/ijd.13540 - France Perret RE, et al. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma. International Journal of Dermatology 56: 527-533, No. 5, May 2017. Available from: URL: http://​doi.​org/​10.​1111/​ijd.​13540 - France
Metadaten
Titel
Ipilimumab/nivolumab/pembrolizumab
Cutaneous erythematous papular eruptions, autoimmune hepatitis and pancreatitis: 11 case reports
Publikationsdatum
01.06.2017
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2017
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-017-31611-9

Weitere Artikel der Ausgabe 1/2017

Reactions Weekly 1/2017 Zur Ausgabe

Case report

Furosemide

Case report

Multiple drugs

Case report

Amphotericin-B

Case report

Montelukast

Case report

Natalizumab